Clinical Trial

Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer

Name: Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer — clinical trial record (NCT07127822)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A randomized controlled phase II study exploring first-line treatment options for recurrent/metastatic MSI-H gastric cancer

Protocol Amendment History 2 changes

critical Recruitment opened 2026-08-06

notable Trial sites expanded: 1 -> 10 locations 2026-08-06

Trial Details

NCT Number	NCT07127822
Lead Sponsor	Peking University Collaborators: Peking University Cancer Hospital & Institute, Qilu Pharmaceutical Group Co., Ltd
Conditions	Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer
Enrollment	106 participants
Start Date	2025-12-15
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-05